Unigene And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treating Type 2 Diabetes
13:11 EDT 15 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
BOONTON, N.J. and COPENHAGEN, Denmark, Aug. 15, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) and Nordic Bioscience today announced, under the Companies' established Joint Development Vehicle (JDV), the preliminary selection of its lead com...
Other Sources for this Article
More From BioPortfolio on "Unigene And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treating Type 2 Diabetes"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
